332
Participants
Start Date
April 25, 2019
Primary Completion Date
September 3, 2021
Study Completion Date
August 8, 2022
Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Placebo
Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
As0011 50020, Duncansville
As0011 50015, Hagerstown
As0011 50056, Sarasota
As0011 50012, Memphis
As0011 50001, Jackson
As0011 50016, St Louis
As0011 50054, Oklahoma City
As0011 50036, Mesquite
As0011 50057, Dallas
As0011 50052, Phoenix
As0011 50058, Phoenix
As0011 50131, Mesa
As0011 50062, Sun City
As0011 50060, Upland
As0011 40004, Brussels
As0011 40003, Genk
As0011 40001, Ghent
As0011 40006, Plovdiv
As0011 40007, Plovdiv
As0011 40005, Sofia
As0011 40008, Sofia
As0011 20040, Beijing
As0011 20021, Chengdu
As0011 20019, Guangzhou
As0011 20034, Hefei
As0011 20024, Nanjing
As0011 20018, Shanghai
As0011 20020, Shanghai
As0011 20026, Shanghai
As0011 20025, Wenzhou
As0011 40011, Brno
As0011 40009, Pardubice
As0011 40013, Prague
As0011 40014, Prague
As0011 40015, Prague
As0011 40016, Prague
As0011 40010, Uherské Hradiště
As0011 40012, Zlín
As0011 40018, Boulogne-Billancourt
As0011 40022, Limoges
As0011 40025, Berlin
As0011 40028, Berlin
As0011 40029, Hamburg
As0011 40024, Hanover
As0011 40027, Herne
As0011 40078, Leipzig
As0011 40026, Ratingen
As0011 40032, Debrecen
As0011 40031, Szeged
As0011 40033, Székesfehérvár
As0011 40080, Szombathely
As0011 20030, Chūōku
As0011 20047, Himeji-shi
As0011 20045, Kita-gun
As0011 20065, Kitakyushu
As0011 20037, Osaka
As0011 20084, Saga
As0011 20048, Saitama
As0011 20031, Sapporo
As0011 20042, Sasebo
As0011 20032, Suita
As0011 20035, Tokyo
As0011 40034, Amsterdam
As0011 40038, Elblag
As0011 40042, Krakow
As0011 40037, Lublin
As0011 40044, Poznan
As0011 40040, Torun
As0011 40041, Warsaw
As0011 40039, Wroclaw
As0011 40043, Wroclaw
As0011 40045, A Coruña
As0011 40046, Córdoba
As0011 40047, Madrid
As0011 40048, Santiago de Compostela
As0011 40049, Seville
As0011 40052, Ankara
As0011 40053, Ankara
As0011 40050, Istanbul
As0011 40057, Edinburgh
As0011 40056, Leeds
As0011 40054, London
As0011 40055, Norwich
UCB Biopharma SRL
INDUSTRY